title: Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential.
authors.affiliation: Department of Dermatology, University of Minnesota School of Medicine, Minneapolis.
authors.forename: H I
authors.initials: HI
authors.lastname: Katz
authors.forename: S E
authors.initials: SE
authors.lastname: Prawer
authors.forename: M J
authors.initials: MJ
authors.lastname: Watson
authors.forename: T A
authors.initials: TA
authors.lastname: Scull
authors.forename: E A
authors.initials: EA
authors.lastname: Peets
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001284:Atrophy / Q000139:chemically induced; D005260:Female; D006801:Humans; D006854:Hydrocortisone; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D009824:Ointments; D011244:Pregnadienediols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D012867:Skin / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D009824:Ointments; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D006854:Hydrocortisone